Peptide, complex of peptide and siRNA, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11306313-B2
Application number	US-202016751783-A
Country	US
Kind code	B2
Filing date	Jan 24, 2020
Priority date	Dec 18, 2013
Publication date	Apr 19, 2022
Grant date	Apr 19, 2022

Abstract

A series of peptides and a peptide-siRNA complex are disclosed, wherein the peptide based complex effectively enhances delivery of siRNA molecules into the cells and release of siRNA in the cell, and improves siRNA mediated gene silencing efficiency of cellular targets. Pharmaceutical compositions that include the complex, as well as a use of the complex in the gene therapy field, are also disclosed.

First claim

What is claimed is:

1. A peptide having the sequence CH 3 (CH 2 ) 16 CONH—B—CONH 2 , wherein B is SEQ ID NO:4 or 5.

2. A complex comprising:
a cargo molecule; and
a peptide having the sequence CH 3 (CH 2 ) 16 CONH—B—CONH 2 , wherein B is SEQ ID NO:4 or 5.

3. The complex according to claim 2 , wherein the cargo molecule and the peptide are coupled non-covalently.

4. The complex according to claim 2 , wherein the particle size of the complex is in a range of from 20 nm to 999 nm.

5. The complex according to claim 2 , wherein the cargo molecule is a nucleic acid.

6. The complex according to claim 5 , wherein the nucleic acid is a short interfering RNA (siRNA).

7. The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio within a range of from 1:1 to 80:1.

8. The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 20:1.

9. The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 40:1.

10. The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 60:1.

11. A pharmaceutical composition containing a complex comprising:
a cargo molecule; and
a peptide having the sequence CH 3 (CH 2 ) 16 CONH—B—CONH 2 , wherein B is SEQ ID NO:4 or 5.

12. A kit used to deliver drugs to a patient, wherein the kit comprises:
a pharmaceutical composition comprising a complex comprising:
a cargo molecule; and
a peptide having the sequence CH 3 (CH 2 ) 16 CONH—B—CONH 2 , wherein B is SEQ ID NO:4 or 5;

one or more electrolytes;
one or more buffers;
a delivery device; and
a container adapted to mix one or more other agents together.

13. The kit according to claim 12 , wherein the cargo molecule and the peptide are coupled non-covalently.

14. The kit according to claim 12 , wherein the particle size of the complex is in a range of from 20 nm to 999 nm.

15. The kit according to claim 12 , wherein the cargo molecule is a nucleic acid.

16. The kit according to claim 15 , wherein the nucleic acid is a short interfering RNA (siRNA).

17. The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio within a range of from 1:1 to 80:1.

18. The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio in a range of from 20:1 to 60:1.

19. The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio of 20:1 or 40:1.

20. A method, comprising:
delivering the pharmaceutical composition of claim 11 to a patient.

Assignees

• Positec Power Tools Suzhou Co Ltd
• Chen Pu

Inventors

• Chen Pu
• Chu Dafeng
• Chen Baoling
• Xu Wen
• Pan Ran

Classifications

• A61K47/42 Primary

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61K9/5169

  Proteins, e.g. albumin, gelatin · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N15/111

  General methods applicable to biologically active non-coding nucleic acids · CPC title

• C12N15/87

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title